234 related articles for article (PubMed ID: 26731754)
41. Impact of rosuvastatin on atherosclerosis in people with HIV at moderate cardiovascular risk: a randomised, controlled trial.
Trevillyan JM; Dart A; Paul E; Cavassini M; Fehr J; Staehelin C; Dewar EM; Hoy JF; Calmy A
AIDS; 2021 Mar; 35(4):619-624. PubMed ID: 33252480
[TBL] [Abstract][Full Text] [Related]
42. Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage.
Coen PM; Flynn MG; Markofski MM; Pence BD; Hannemann RE
Metabolism; 2009 Jul; 58(7):1030-8. PubMed ID: 19411087
[TBL] [Abstract][Full Text] [Related]
43. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
44. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study).
Ikeda K; Takahashi T; Yamada H; Matsui K; Sawada T; Nakamura T; Matsubara H;
Eur J Prev Cardiol; 2013 Dec; 20(6):1069-79. PubMed ID: 22689416
[TBL] [Abstract][Full Text] [Related]
45. Oxidized low-density lipoprotein, matrix-metalloproteinase-8 and carotid atherosclerosis in spinal cord injured subjects.
Paim LR; Schreiber R; Matos-Souza JR; Silva AA; Campos LF; Azevedo ER; Alonso K; de Rossi G; Etchebehere M; Gorla JI; Cliquet A; Nadruz W
Atherosclerosis; 2013 Dec; 231(2):341-5. PubMed ID: 24267248
[TBL] [Abstract][Full Text] [Related]
46. Atorvastatin therapy is associated with improvement of oxidized low-density lipoprotein cholesterol levels, which correlates with the degree of stenosis in patients with carotid atheromatosis with and without prior angioplasty.
Kougialis S; Skopelitis E; Gialernios T; Nikolaou S; Kroustalis A; Katsadorou E; Gialernios K; Zervou A; Gika E; Polydorou A; Polydorou V; Drakoulis C; Iliopoulos N; Dermitzakis I; Mpilinis H; Polydorou A
Int Angiol; 2010 Aug; 29(4):338-47. PubMed ID: 20671652
[TBL] [Abstract][Full Text] [Related]
47. The CD14 C-260T single nucleotide polymorphism (SNP) modulates monocyte/macrophage activation in treated HIV-infected individuals.
Rajasuriar R; Kong YY; Nadarajah R; Abdullah NK; Spelman T; Yuhana MY; Ponampalavanar S; Kamarulzaman A; Lewin SR
J Transl Med; 2015 Jan; 13():30. PubMed ID: 25622527
[TBL] [Abstract][Full Text] [Related]
48. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans.
Ky B; Burke A; Tsimikas S; Wolfe ML; Tadesse MG; Szapary PO; Witztum JL; FitzGerald GA; Rader DJ
J Am Coll Cardiol; 2008 Apr; 51(17):1653-62. PubMed ID: 18436117
[TBL] [Abstract][Full Text] [Related]
49. Biologically implausible carotid intima-media thickness measurement values: effects on rate of change over time.
Peters SA; den Ruijter HM; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Evans GW; Raichlen JS; Bots ML;
Curr Med Res Opin; 2012 Jun; 28(6):891-9. PubMed ID: 22536884
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
Farnier M; Jones P; Severance R; Averna M; Steinhagen-Thiessen E; Colhoun HM; Du Y; Hanotin C; Donahue S
Atherosclerosis; 2016 Jan; 244():138-46. PubMed ID: 26638010
[TBL] [Abstract][Full Text] [Related]
51. Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275).
Nixon DE; Bosch RJ; Chan ES; Funderburg NT; Hodder S; Lake JE; Lederman MM; Klingman KL; Aberg JA;
J Clin Lipidol; 2017; 11(1):61-69. PubMed ID: 28391912
[TBL] [Abstract][Full Text] [Related]
52. Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV.
Toribio M; Fitch KV; Sanchez L; Burdo TH; Williams KC; Sponseller CA; McCurdy Pate M; Aberg JA; Zanni MV; Grinspoon SK
AIDS; 2017 Mar; 31(6):797-806. PubMed ID: 28252528
[TBL] [Abstract][Full Text] [Related]
53. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis-design, rationale, and methodology of the METEOR-China study.
Wang Y; Wang A; Li H; Li Z; Hu B; Li X; Zheng H; Fu L; Hu H; Nie Z; Qin Y; Zhao B; Wei D; Karlson BW; Bots ML; Chen Y; Wang Y
Trials; 2020 Nov; 21(1):921. PubMed ID: 33176842
[TBL] [Abstract][Full Text] [Related]
54. The oxidized low-density lipoprotein/β2-glycoprotein I complex is associated with abdominal obesity in healthy middle-aged men.
Kraml PJ; Syrovátka P; Potočková J; Anděl M
Ann Nutr Metab; 2013; 62(1):7-13. PubMed ID: 23171597
[TBL] [Abstract][Full Text] [Related]
55. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.
Choi SH; Chae A; Miller E; Messig M; Ntanios F; DeMaria AN; Nissen SE; Witztum JL; Tsimikas S
J Am Coll Cardiol; 2008 Jul; 52(1):24-32. PubMed ID: 18582631
[TBL] [Abstract][Full Text] [Related]
56. Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis.
Lopez LR; Salazar-Paramo M; Palafox-Sanchez C; Hurley BL; Matsuura E; Garcia-De La Torre I
Lupus; 2006; 15(2):80-6. PubMed ID: 16539278
[TBL] [Abstract][Full Text] [Related]
57. A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk.
Masiá M; Bernal E; Padilla S; García N; Escribano JC; Martínez E; Gutiérrez F
J Antimicrob Chemother; 2009 Sep; 64(3):589-98. PubMed ID: 19625372
[TBL] [Abstract][Full Text] [Related]
58. Augmentation index and carotid intima-media thickness are differently related to age, C-reactive protein and oxidized low-density lipoprotein.
Kampus P; Kals J; Ristimäe T; Muda P; Ulst K; Zilmer K; Salonen RM; Tuomainen TP; Teesalu R; Zilmer M
J Hypertens; 2007 Apr; 25(4):819-25. PubMed ID: 17351374
[TBL] [Abstract][Full Text] [Related]
59. Disease Activity, Oxidized-LDL Fraction and Anti-Oxidized LDL Antibodies Influence Cardiovascular Risk in Rheumatoid Arthritis.
Nowak B; Madej M; Łuczak A; Małecki R; Wiland P
Adv Clin Exp Med; 2016; 25(1):43-50. PubMed ID: 26935497
[TBL] [Abstract][Full Text] [Related]
60. Oxidized low-density lipoproteins, autoantibodies against oxidized low-density lipoproteins and carotid intima media thickness in a clinically healthy population.
Chen HW; Kuo CL; Huang CS; Kuo SJ; Liu CS
Cardiology; 2008; 110(4):252-9. PubMed ID: 18073481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
